I had high expectations going into the hot-topics session about the ongoing Senate investigation into pharmaceutical companies' educational grants at the Alliance for CME annual conference — but I left disappointed and concerned about the CME community's lack of response to this extremely important development. (See news story, page 14.) During the session, Bruce Bellande, PhD, executive director, Alliance for CME, said that he had initiated productive conversations with a Senate Finance ...

Register for Complete Access (Valid Email Required)

By registering on MeetingsNet now, you'll not only gain access to CME's Voice in Washington, you'll get exclusive access to a large archive of premium content.

Already registered? here.